Roivant Sciences (ROIV) traded sharply higher after its subsidiary Immunovant (IMVT) posted initial results from a Phase 2 trial evaluating its lead asset IMVT-1402 in rheumatoid arthritis, an ...

Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the 10 Stocks With Insane Returns Right Now. Roivant Sciences grew its share prices by 14.89 percent on Wednesday to close at $32.41 apiece, as investors ...

Roivant financial position is robust, ending the quarter with $4.3 billion in cash and a management-asserted runway to ...

View Roivant Sciences Ltd. ROIV stock quote prices, financial information, real-time forecasts, and company news from CNN.

Key Points Interested in Roivant Sciences Ltd.? Here are five stocks we like better. IMVT-1402 posted encouraging preliminary results in difficult-to-treat rheumatoid arthritis, with about 73% of ...

IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its ...

Transaction value based on SEC Form 4 reported price ($21.00); post-transaction value based on Dec. 12, 2025 market close, yielding a position value of $2,993,835,324.94. Immunovant, Inc. is a ...

In May 2026, Roivant Sciences reported fourth-quarter 2026 results showing sales of US$2.52 million, a swing to quarterly net income of US$302.99 million, and full-year 2026 sales of US$8.26 million ...

Roivant Sciences (NASDAQ:ROIV) is gearing up to announce its quarterly earnings on Friday, 2026-02-06. Here's a quick overview of what investors should know before the release. Analysts are estimating ...

Immunovant develops monoclonal antibody therapeutics, with batoclimab as its lead candidate targeting autoimmune diseases such as myasthenia gravis, thyroid eye disease, and warm autoimmune hemolytic ...